Document:

Unassociated Document

Exhibit 10.3

 

 

THIS BONUS PAYMENT AGREEMENT

 

Entered into as of the 7th day of October, 2010

 

BETWEEN:

 

Mr. Zhen Jiang Wang, is the CEO of Kun Ming Xin Yuan Tang Pharmacies Co (“XYT”) and the Chairman and CEO of a First China Pharmaceutical Group, Inc.

 

(“Wang”)

 

AND:

 

First China Pharmaceutical Group, Inc. a publically traded company traded under the symbol FCPG

 

(“FCPG”)

 

WHEREAS:

 

	
  

	
A.

	
FCPG wishes to retain Wang as the CEO of XYT and the Chairman and CEO of FCPG; and

 

	
  

	
B.

	
FCPG and Wang wish to enter into a Bonus Payment Agreement for their mutual benefit and subject to the terms outlined in this Agreement.

 

NOW THEREFORE in consideration of the premises and mutual covenants herein contained, the parties hereto agree as follows:

 

1.0           FCPG agrees to pay Wang a bonus payment of two percent (2%) of the quarterly gross sales of XYT, as calculated and disclosed in the financial statements of XYT included in the consolidated financial statements of FCPG.

 

2.0           The bonus payment shall be made to Wang on a quarterly basis, within fifteen (15) days after the filing of a Form 10-K or Form 10-Q with the SEC containing financial statements of FCPG unless otherwise instructed by Wang.

 

3.0           The bonus payment shall be made to Wang shall not exceed one and a half million US Dollars ($1,500,000) each fiscal year.

 

4.0           At his sole discretion, Wang can reduce or modify the amount due to him as long as it does not exceed, two percent (2%) of the quarterly gross sales of XYT, as calculated and disclosed in the financial statements included in the consolidated financial statements of FCPG.

 

5.0           This Agreement may be executed in counterparts.

 

 

  

  

  

 

IN WITNESS WHEREOF the parties hereto have executed this Agreement the day and year first above written.

 

 

 

	
/s/ Gregory D. Tse

	
Mr. Gregory D. Tse

	
On behalf of the Board of First China Pharmaceutical Group, Inc.

	  
	
     

 

 

 

	
/s/ Zhen Jiang Wang

	
Mr. Zhen Jiang WangUnassociated Document

Exhibit 10.3(a)

 

October 8, 2010

 

Mr. Gregory D. Tse

 

Member of the Board

 

First China Pharmaceutical Group, Inc.

 

I, Mr. Zhen Jiang Wang hereby amend the Bonus Payment Agreement that I entered into with First China Pharmaceutical Group, Inc. on October 7, 2010 to reflect the following:

 

	
1.

	
In order to ensure that the company has sufficient working capital to execute its business plan, I hereby waive my right to receive any bonus payments as provided in the Bonus Payment Agreement dated October 7, 2010, for the Fiscal Year of First China Pharmaceutical Group, Inc. ending March 31, 2011.

 

	
2.

	
No amounts due for the Fiscal Year of First China Pharmaceutical Group, Inc. ending March 31, 2011 will be carried forward.  I absolve all interests in any payments due to me for the Fiscal Year of First China Pharmaceutical Group, Inc. ending March 31, 2011.

 

	
3.

	
By May 30, 2011, I will inform the Board of First China Pharmaceutical Group, Inc. of my intentions of bonus payments due to me, as provided in the Bonus Payment Agreement dated October 7, 2010, for all or part of the Fiscal Year of First China Pharmaceutical Group, Inc. ending March 31, 2012.

 

 

 

 

 

	
/s/ Zhen Jiang Wang

	  
	
Mr. Zhen Jiang Wang

	  
	
     

 

 

 

	  
	
/s/ Gregory D. Tse

	  
	
WitnessUnassociated Document

 

Exhibit 10.12

 

MAJORITY SHAREHOLDER STATEMENT

Affected by the worldwide financial crisis, New Oriental Energy & Chemical Corp. failed to raise the capital from stock market as planed to complete the infrastructure of the 200,000 tons methanol production line. Due to the shortage of the capital, the production line infrastructure is not completed but New Oriental Energy & Chemical Corp. had input over RMB200M into the construction. The use of funds for the infrastructure induced the shortage of the working capital of our company.

But myself and company’s management, also our shareholders believe that the difficulties is temporary. After almost two years of the bear market for our products, the market price for all our products increased tremendously from August and all the products manufacture are profitable. The market proves the opportunity for company’s operation. As the majority shareholder of New Oriental Energy & Chemical Corp., My affiliated company and myself as individual had combined input into company RMB90M accumulatively up to today. I hereby make the commitment that I extend the term of these loans for another year and I will not demand the return of the loan unless New Oriental Energy & Chemical
Corp.’s financial status fully recovered and has the capacity to return the loan. I also commit that my affiliated company and mys
elf will continuously support the capital of New Oriental Energy & Chemical Corp., I will also use my political influence as member of the National Committee of CPPCC to coordinate with government agencies and financial institutions to enforce the government support to NOEC, to incentive the M&A with capital extensive companies and to use my affiliated company to act as the guarantor for NOEC’s loans.

Xingyang Hongchang Channel Gas Engineering Co., Ltd.

CEO: Chen Siqiang

Nov 15, 2010Unassociated Document

 

Exhibit 10.13

 

Approval on Solutions Relating to Start-up Capital for Henan Jinding Chemical Co., Ltd.

According to the reports from the management of Henan Jinding Chemical Co., Ltd. (“Jinding”), after the Spring Festival, with the peak season of consumption of fertilizer and downstream enterprises of methanol resuming production, the market conditions will further improved for the products of Jinding. Meanwhile, the purchase price of raw coal decreased as the temperature is rising and coal production has started. Equipment condition and the staffing are ready to start production at any time. The only problem is lack of start-up capital. According to this circumstance, I requested a subsidiary of our group to lend short-term loan of RMB 20M to Jinding for one year. The loan is expected to be
placed by the end of February, 2011 and no later than early March as start‐up capital.

Xinyang Hongchang Group

CEO:  Chen Siqiang

February 19, 2011Unassociated Document

CONVERTIBLE NOTE

$ 1,250,000.00

Maturity Date :  February 15, 2013

FOR VALUE RECEIVED, the undersigned CytoSorbents Corporation (the “Company”), promises to pay in equity as set forth below on or before February 15, 2013, to _______________ (“Creditor"), at New York, NY the principal sum of one million two hundred fifty thousand dollars ($1,250,000.00) (the “Principal”), together with interest accruing thereon at the rate of 8% per annum, payable on or before maturity of the Note:

 

The Note will be subordinate to any future debt financing.

	
Conversion into New Financing: In the event that at any time during the term of the Note,  the Company closes on any debt or equity financing in an aggregate amount greater or equal to $750,000 including any equity financing or any financing which provides for a right to convert into equity (such financing shall be referred to as the “New Financing”), and if any principal and interest owed under this Note remains outstanding, the outstanding principal and interest in whole or in part shall, at the sole option of the Creditor, be exchanged for the equivalent dollar amount of the package of securities sold in the New Financing.  The Company shall notify the Creditor in writing within five (5) business days
of closing the New Financing and the Creditor shall have thirty (30) days to exercise this option from the receipt of the notice from the Company of the New Financing.

	
 In the event that the Creditor chooses not to convert the outstanding principal and interest owed under the Note in accordance with the New Financing and during the term of the Note, the Company closes on an additional New Financing, debt or equity, in an aggregate amount greater or equal to $750,000 (such additional financing shall be referred to as the “Additional New Financing”), and if any principal and interest remains outstanding under the Note then the outstanding principal and interest in whole or in part may, at the sole option of the Creditor, be exchanged for the equivalent dollar amount of the package of securities sold in the Additional New Financing.  The Company shall notify the Creditor in writing within five (5) business days of closing the
Additional New Financing and the Creditor shall have thirty (30) days to exercise this option from the receipt of the notice from the Company of the Additional New Financing.  In the event the Creditor chooses not to convert into such Additional New Financing his right shall be deemed waived, but solely for that particular transaction, and shall remain in full effect for any subsequent Additional New Financings, during the term of the Note as long as the Creditor continues to hold any Principal and interest outstanding under the Note.

Conversion in accordance with terms of Note: Alternatively at any time during the term of the Note, at the sole option of the Creditor, the outstanding principal and interest owed under the Note, in whole or in part, may be converted into Common Stock of the Company at a rate of $0.10 per share of Common.  At the maturity of the Note, any outstanding principal and interest will be converted into Common Stock of the Company at a rate of $0.10 per share of Common.  Based upon the above, this note will be repaid through the conversion into equity and the Company will have no obligation to repay in cash.

Warrants: 100% Warrant coverage as follows: The Company will issue the Creditor five-year warrants (the “Warrants”) to purchase :

	
  

	
1)

	
That number of shares of Common Stock equal to the quotient obtained by dividing (x) 50% of the Principal, by (y) $0.10, with the resulting number of shares having an exercise price equal to $0.10 per share of Common Stock.

	
  

	
2)

	
That number of shares of Common Stock equal to the quotient obtained by dividing (x) 25% of the Principal, by (y) $0.125, with the resulting number of shares having an exercise price equal to $0.125 per share of Common Stock.

	
  

	
3)

	
That number of shares of Common Stock equal to the quotient obtained by dividing (x) 25% of the Principal, by (y) $0.15, with the resulting number of shares having an exercise price equal to $0.15 per share of Common Stock.

 

  

  

  

Cashless Exercise of Warrants: If the current market value of the Company’s Common Stock (as defined below) is greater than the warrant exercise price, in lieu of delivering the exercise price in cash or check the Creditor may elect to exchange the warrants, in whole or in part, to receive in exchange that number of shares of Common Stock equal to the value of these Warrants or portion thereof being exercised (the "Net Issue Exercise").  If the Creditor wishes to elect the Net Issue Exercise, the Creditor shall notify the Company of his election in writing at the time the Creditor delivers to the Company the notice of exercise in the form attached hereto along with the surrender of the warrant at the principal office of the
Company.  In the event the Creditor shall elect the Net Issue Exercise, the Creditor shall receive upon exercise of the Warrants that number of shares of Common Stock equal to (A) the product of (i) the number of shares purchasable under this warrant by means of a cash exercise, or portion thereof being exercised, and (ii) the excess of the current market value (as defined below) per share over the warrant exercise price per share, divided by (B) the current market value, as defined below, of each share.  Current market value of the Common Stock shall be determined as follows:

 

    (i)      If the shares are listed on a national securities exchange, listed for trading on the Nasdaq Stock Market, listed for trading over the counter, bulletin board or pink sheets, the current market value shall be the volume weighted average of the reported closing sale prices of the shares on such exchange or system for five (5) consecutive business trading days ending on the last business trading day prior to the date of exercise of this warrant; or

 

    (ii)     If the shares are no longer listed as in (i) above, the current market value shall be the volume weighted average of the reported closing sale prices of the shares for the last fifteen (15) reported consecutive business trading days on such exchange or system immediately preceding 180 business trading days from the delisting of the shares, within the term of the Note; or

 

    (iii)    If there were no such sales during the term of the Note, the most significant recent sale, as determined in a reasonable manner by the Directors of the Company.

	
Right of First Refusal:  Defined as follows: If during the Term of the Note and as long as the Creditor continues to have all or a portion of their original outstanding principal balance of the Note, the Company receives an offer that is approved by the Company’s Board of Directors (the "BOD") for  an equity financing of less than $750,000 that values the Company on a pre-money basis at or less than $35 million on a fully-diluted basis (the “Offer”), the Creditor will have a right of first refusal to participate in such financing  in whole or in part up to a maximum dollar amount of their original Principal investment in this Note, but not to exceed the proposed amount in the
Offer. However, in the event several different Creditors express written notice of intention to participate in the proposed Offer, the BOD at its sole discretion, may limit the maximum investment from each Creditor to be capped at the percentage of the Offer equal to the individual Creditor's pro rata ownership percentage of the entire Principal raised in the aggregate in this Note.  Creditor’s participation in such financing will require closing within the time frame stipulated in the Offer.  The Company will notify the Creditor within five (5) days of receipt of the Offer and if the Company does not receive notice from the Creditor of its intention to participate in the proposed financing within five (5) days of actual receipt by the Creditor of such notice, then such right of first refusal shall be deemed waived, but solely for the particular
transaction and shall remain in full effect for subsequent transactions during the term of the Note. The time period the Creditor has to exercise this Right of First Refusal and deliver payment for their investment in the financing of the Offer shall be the later date of either i) fifteen (15) days from the Creditor’s receipt of the notice from the Company of the Creditor’s approved amount of participation in the Offer, or (ii) the closing date stipulated in the Offer.

Compliance with Securities Laws: (i)   The Creditor, by acceptance hereof, acknowledges that this Note and the shares of Common Stock to be issued upon conversion hereof are being acquired solely for the Creditor’s own account and not as a nominee for any other party, and for investment, and that the Creditor will not offer, sell or otherwise dispose of this Note or any shares of Common Stock to be issued upon conversion hereof except pursuant to an effective registration statement, or an exemption from registration, under the Securities Act and any applicable state securities laws. (ii)   Except as provided in paragraph (iii) below, this Note
and all certificates representing shares of Common Stock issued upon conversion hereof shall be stamped or imprinted with a legend in substantially the following form:

 

THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

 (iii)   The Company agrees to reissue the certificates representing any of the Common Stock, without the legend set forth above if at such time, prior to making any transfer of any such securities, the Creditor shall give written notice to the Company describing the manner and terms of such transfer. Such proposed transfer will not be effected until: (a) either (i) the Company has received an opinion of counsel reasonably satisfactory to the Company, to the effect that the registration of such securities under the Securities Act is not required in connection with such proposed transfer, (ii) a registration statement under the Securities Act covering such proposed disposition has been filed by the
Company with the United States Securities and Exchange Commission and has become effective under the Securities Act, or (iii) the Company has received other evidence reasonably satisfactory to the Company that such registration and qualification under the Securities Act and state securities laws are not required.

  

  

  

 

This Note and any of its terms may be changed, waived, or terminated only by a written instrument signed by the party against which enforcement of that change, waiver, or termination is sought.

If any action is instituted to collect this Note or enforce any terms hereof, the Company promises to pay all legal fees and other expenses reasonably incurred by the Creditor in connection therewith.

The Company hereby waives notice of presentment or demand for payment, protest or notice of nonpayment or dishonor and all other notices or demands relative to this instrument.

 

 

This Note is made in, governed by, and shall be construed in accordance with the laws of the State of New York.

CYTOSORBENTS CORPORATION

By_______________________________02/15/11

Name: Phillip Chan

Title:  Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]